Jun 27 |
Azitra announces 1-for-30 reverse stock split
|
Jun 27 |
Azitra, Inc. Announces Reverse Stock Split
|
Jun 17 |
AZTR: Historical and Financial Review
|
Jun 6 |
AZTR: Netherton Syndrome Review and ATR-12 Clinical Trial
|
Jun 3 |
AZTR: Pipeline Review
|
May 31 |
Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
|
May 17 |
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
|
May 10 |
Azitra GAAP EPS of -$0.15
|
May 10 |
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
|
May 9 |
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
|